Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists
JAMA · 2024
DOI: 10.1001/jama.2024.7062 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA, 2024. Verfasst von Jamy D Ard und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Life Style, Obesity. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Pat Hoddinott, MB, BS, PhD; Catriona O'Dolan, PhD; Lisa Macaulay, PhD; Stephan U. Dombrowski, PhD; James Swingler, MSc; Seonaidh Cotton, PhD; Alison Avenell, MD, MB, BS; Abraham M. Getaneh, PhD; Cindy Gray, PhD; Kate Hunt, PhD; Frank Kee, MD; Alice MacLean, PhD; Michelle McKinley, PhD; Claire Torrens, MSc; Katrina Turner, PhD; Marjon van der Pol, PhD; Graeme MacLennan, MSc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
- Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Zitieren
APA
Ard, J. D., Lewis, K. H., & Moore, J. B. (2024). Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists. JAMA. https://doi.org/10.1001/jama.2024.7062
Vancouver
Ard JD, Lewis KH, Moore JB. Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists. JAMA. 2024. doi:10.1001/jama.2024.7062
BibTeX
@article{Ard2024,
author = {Ard, Jamy D and Lewis, Kristina H and Moore, Justin B},
title = {Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.7062}
}
EUVIMED